rs138900040
Positions:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 3P and 5B. PM1PP2BP4_StrongBS2_Supporting
The NM_000552.5(VWF):c.3868G>A(p.Glu1290Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000114 in 1,613,982 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.00058 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000065 ( 0 hom. )
Consequence
VWF
NM_000552.5 missense
NM_000552.5 missense
Scores
5
9
5
Clinical Significance
Conservation
PhyloP100: 2.98
Genes affected
VWF (HGNC:12726): (von Willebrand factor) This gene encodes a glycoprotein involved in hemostasis. The encoded preproprotein is proteolytically processed following assembly into large multimeric complexes. These complexes function in the adhesion of platelets to sites of vascular injury and the transport of various proteins in the blood. Mutations in this gene result in von Willebrand disease, an inherited bleeding disorder. An unprocessed pseudogene has been found on chromosome 22. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM1
In a helix (size 15) in uniprot entity VWF_HUMAN there are 9 pathogenic changes around while only 0 benign (100%) in NM_000552.5
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), VWF. . Gene score misZ 0.98969 (greater than the threshold 3.09). Trascript score misZ 3.5064 (greater than threshold 3.09). GenCC has associacion of gene with von Willebrand disease type 2M, hereditary von Willebrand disease, von Willebrand disease type 2B, von Willebrand disease type 2N, von Willebrand disease 2, von Willebrand disease type 2A, von Willebrand disease 3, von Willebrand disease 1.
BP4
Computational evidence support a benign effect (MetaRNN=0.03959188).
BS2
High AC in GnomAd4 at 89 AD gene. Variant has AC lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VWF | NM_000552.5 | c.3868G>A | p.Glu1290Lys | missense_variant | 28/52 | ENST00000261405.10 | NP_000543.3 | |
VWF | XM_047429501.1 | c.3868G>A | p.Glu1290Lys | missense_variant | 28/52 | XP_047285457.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VWF | ENST00000261405.10 | c.3868G>A | p.Glu1290Lys | missense_variant | 28/52 | 1 | NM_000552.5 | ENSP00000261405 | P1 | |
VWF | ENST00000539641.1 | n.666G>A | non_coding_transcript_exon_variant | 3/3 | 3 | |||||
VWF | ENST00000538635.5 | n.421-25616G>A | intron_variant, non_coding_transcript_variant | 4 |
Frequencies
GnomAD3 genomes AF: 0.000585 AC: 89AN: 152198Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
89
AN:
152198
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000207 AC: 52AN: 251084Hom.: 0 AF XY: 0.000228 AC XY: 31AN XY: 135714
GnomAD3 exomes
AF:
AC:
52
AN:
251084
Hom.:
AF XY:
AC XY:
31
AN XY:
135714
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000650 AC: 95AN: 1461666Hom.: 0 Cov.: 38 AF XY: 0.0000564 AC XY: 41AN XY: 727142
GnomAD4 exome
AF:
AC:
95
AN:
1461666
Hom.:
Cov.:
38
AF XY:
AC XY:
41
AN XY:
727142
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000584 AC: 89AN: 152316Hom.: 0 Cov.: 32 AF XY: 0.000644 AC XY: 48AN XY: 74482
GnomAD4 genome
AF:
AC:
89
AN:
152316
Hom.:
Cov.:
32
AF XY:
AC XY:
48
AN XY:
74482
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
13
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
32
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 15, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 07, 2019 | The VWF c.3868G>A; p.Glu1290Lys variant (rs138900040), to our knowledge, is not reported in the medical literature or gene-specific databases in association with von Willebrand disease. This variant is found in the African population with an overall allele frequency of 0.25% (63/24954 alleles) in the Genome Aggregation Database. The glutamate at codon 1290 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious, although a modeling study incorporating population data and VWF levels suggested the p.Glu1290Lys variant had a low probability of being disease-causing (Cheng 2016). However, given the lack of clinical and functional data, the significance of the p.Glu1290Lys variant is uncertain at this time. References: Cheng Y et al. Group association test using a hidden Markov model. Biostatistics. 2016 Apr;17(2):221-34. - |
not provided Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The VWF p.Glu1290Lys variant was not identified in the literature nor was it identified in Cosmic or LOVD 3.0. The variant was identified in dbSNP (ID: rs138900040) and in ClinVar (classified as a VUS by Quest Diagnostics Nichols Institute San Juan Capistrano). The variant was also identified in control databases in 71 of 282484 chromosomes at a frequency of 0.000251 (Genome Aggregation Database Feb 27, 2017) and was observed in the following populations: African in 63 of 24954 chromosomes (freq: 0.002525), Latino in 5 of 35440 chromosomes (freq: 0.000141), South Asian in 2 of 30616 chromosomes (freq: 0.000065) and European (non-Finnish) in 1 of 128814 chromosomes (freq: 0.000008), while the variant was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), and Other populations. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.Glu1290 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Uncertain
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D
M_CAP
Pathogenic
D
MetaRNN
Benign
T
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at